



# International Journal of Multidisciplinary Research and Growth Evaluation.

## Evaluation of Antipyretic and Analgesic Activity of *Ipomoea Quamoclit*

Vaddeboina Sowmya <sup>1\*</sup>, Malleboina Shruthi <sup>2</sup>, Papagatla Poli Reddy <sup>3</sup>, KNV Rao <sup>4</sup>

<sup>1-4</sup> Department of Pharmacology, Nalanda College of Pharmacy, Nalgonda, Cherlapalli, Telangana, India

\* Corresponding Author: Vaddeboina Sowmya

### Article Info

ISSN (online): 2582-7138

Volume: 05

Issue: 06

November-December 2024

Received: 20-09-2024

Accepted: 22-10-2024

Page No: 708-713

### Abstract

Pharmacological studies were conducted with ipomoea quamoclit extract the experimental animals for evaluating the analgesic, and antipyretic activities. In the analgesic test, ipomoea quamoclit elicited inhibitory intensity on acetic acid-induced writhing response and on the late phase of formalin test but possessed only a weak effect on the tail-flick response and on the early phase of formalin test. The ipomoea quamoclit extract also elicited antipyretic in animals. In addition, ipomoea quamoclit extract showed an anti-antipyretic activities effect when tested in ethyl phenylpropionate (EPP) and arachidonic acid (AA)-induced.

**Keywords:** ipomoea quamoclit, antipyretic, analgesic

### Introduction

#### Background information

Fever refers to an increase in body temperature beyond the regulatory set point of 36.5 -37.5 °C (98- 100°F). This increase in temperature triggers muscle tone and shivering. Fever signifies several illnesses. Symptoms of fever include sweating, chills, a sensation of cold and other subjective sensations. The absence of these symptoms when the temperature is high can be a pointer to a serious illness <sup>[1]</sup>. Fever may be caused by infections caused by parasites, viruses, bacteria and immune reactions (including defects in collagen, immunological abnormalities and acquired immunodeficiency <sup>[2]</sup>. Fever can also be a result of the destruction of tissues during trauma, local necrosis (infarction), an inflammatory reaction in tissues and vessels (flebitis, arthritis), pulmonary infarction, and rhabdomyolysis <sup>[3]</sup>.

In humans, temperature regulation is controlled by the thermoregulatory center in the hypothalamus <sup>[4]</sup>. The input to the hypothalamus comes from peripheral as well as central thermo-receptors. Research has revealed neural substrates for thermoregulatory control <sup>[5]</sup>. The peripheral and central thermoreceptors situated beneath the skin are of two subtypes namely those that respond to cold and those responding to warmth <sup>[6]</sup>. The warm central thermo receptors are located in the hypothalamus, spinal cord, viscera, and great veins, which are more numerous than cold thermo-receptors <sup>[7]</sup>.

Pain is an unpleasant sensory affliction and emotional experience usually associated with actual or potential tissue damage or described in terms of such damage <sup>[8]</sup>. Pain serves as a warning signal against disturbances. Pain is aimed at protecting the organism but often leads to discomfort <sup>[9]</sup>. We have two types of pain nociceptive and pathological pain. Nociceptive pain is also known as acute pain, which usually accompanies noxious stimuli warning of impending tissue damage <sup>[10]</sup>. Pathological pain, according to its cause, is divided into inflammatory pain and neuropathic pain, both belong to chronic pain <sup>[11]</sup>. Chronic pain completes the list of largest medical health problems in countries with many low-income cadres of people <sup>[12]</sup>. Treatment of pain and related problems calls for a good understanding of how pain signals are initially interpreted and subsequently transmitted and perpetuated <sup>[13]</sup>.

Antinociceptives such as opiates and non-steroidal anti-inflammatory drugs (NSAIDs) have many side effects <sup>[14]</sup>. Pain studies, treatment and management have made important progress now, but remain underestimated and poorly managed mostly in developing countries <sup>[15]</sup>. This leads to pain among hospitalized patients is extensive, and significantly more <sup>[16]</sup>.

## Materials and Methods

### Collection and preparation of plant materials

Fresh plant aerial part of the selected plant was collected from Ranga Reddy District, Hyderabad, and Telangana. These plants are believed by the locals to have medicinal value against various ailments. The plant materials were identified by Dr. Madhaban Chetty, Asst. Professor, Sri Venkateswar University, Tirupati, Andhra Pradesh. The collected plant part was first washed 2–3 times using tap water, to remove adherent particles and dried under shade for com. Preparation of plant extracts was carried out using a protocol as described by Nostro *et al.* (2000) [17]. The dried material was ground to a fine powder using a grinder and passed through a mesh sieve. The powdered materials were kept at room temperature away from direct sunlight in closed dry khaki paper bags.

### Extraction

The coarse powder of aerial *Ipomoea quamoclit* was packed tightly in the soxhlet apparatus and extracted with ethanol for 72 hours with occasional shacking maintained at 60°C throughout the extraction process. The extract was concentrated to of its original volume by evaporation. The resulting ethanolic extract of aerial *Ipomoea quamoclit* was subjected to phytochemical study.

### Procedure:

The animals were divided into two groups and each group consisted of five mice. The defined or fixed dose level of extracts (2000 mg/kg) was given orally to identify a dose producing evident toxicity. The animals were observed continuously for 2 hours for behavioral, neurological and autonomic profiles. The toxicity signs were observed after 24 hours till fourteen days for any lethality or death.

### Antipyretic

#### Experimental animals

Male Swiss albino rats were used in this study. The rats were aged between 2 and 3 months and with an average weight of 150 grams. The animals were obtained from our institution animal house. They were kept in approved polyethylene cages at room temperature (25±2°C) with 40 to 60 % humidity and 12h dark hours and 12h light cycle. They were provided with standard diet *ad libitum* and water [18].

### Preparation of treatment doses

The choice of doses used in this study was arrived at after oral acute toxicity test. The different treatment doses used in this study were prepared as follows, 25, 50, 100, 100, 150, 200 and 250mg/kg body weight dose level, were prepared by dissolving 0.005g, 0.01g, 0.02g, 0.03g, 0.04g and 0.05g of the extract respectively in 0.3ml of 3% DMSO and 0.7ml of normal saline was added. To prepare 100mg/kg body weight aspirin each rat needed 13mg of the drug dissolved in 0.5ml of normal saline. Therefore, to prepare a larger volume of the drug, 0.5 g of aspirin was dissolved in 19.23ml of normal saline. All the extracts and solutions administered were freshly prepared.

### Experimental design

Experimental rats were split into six groups of five animals each (n = 5).

**Group I** (normal control) comprised normal rats that were administered with 3% DMSO.

**Group II** (negative control) comprised rats that had been

induced with pyrexia using 20% turpentine. They were administered with 3% DMSO.

**Group III** (positive control) comprised turpentine-induced pyretic rats that were administered with aspirin (100mg/kg bw).

**Group IV** comprised of turpentine induced pyretic rats that were administered with extract dose of 150mg/kg bw.

**Group V** comprised turpentine induced pyretic rats that were administered with extract dose of 200mg/kg bw.

**Group VI** comprised of turpentine induced pyretic rats that were administered with extract dose of 250mg/kg body weight.

The body temperature of rats in all the groups was taken after fever induction and at hourly intervals following administration of treatments for four hours [16]. Approximately 3cm of a well-lubricated digital thermometer (thermistor probe®) was inserted into the anal region of the rats to measure the rectal temperature. The thermistor animals in the experimental group were taken using both types of thermometers and compared.

The thermistor probe® was first quantified against a mercury thermometer, where temperatures of the animals in the experimental groups were recorded using both thermometers and compared. The baseline/initial mean rectal temperature was calculated by measuring the rectal temperature of rats at fifteen minutes intervals for 1 hour before the induction of fever.

The rectal temperatures of rats were measured and recorded at hourly intervals for 4 hours after the administration of different treatments. The rats whose rectal temperatures rose by one degree Celsius one hour after intraperitoneal injection of turpentine (20mg/kg bw) were termed pyretic and were used for the studies [16]. The difference in rectal temperatures before and after treatments was obtained and the % inhibition in the rectal temperature computed according to the formula as described by Hukkeriet *al.*, 2006; Yemitan and Adeyemi, 2017 [19, 20].

$$\% \text{ inhibition of pyrexia} = \frac{B - C_n}{B} \times 100$$

Where,

B - Rectal temperature at one hour following turpentine injection

C<sub>n</sub> - Rectal temperature after treatments.

### Analgesic Activity

#### Preparation of treatment doses

The preparation of extract doses was done as per the procedure described in antipyretic activity. To prepare 2.5% formalin, 97.5 ml of distilled water was added to 2.5 ml of formalin. To prepare diclofenac.

### Experimental animals

Swiss albino mice of both sexes aging between 5-6 weeks of approximately 20g were used to assess for the analgesic activities of the extracts. The animals were obtained from our institution animal house. They were kept in approved polyethylene cages at room temperature (25±2°C) with 40 to 60 % humidity and 12h dark hours and 12h light cycle. They were provided with standard diet *ad libitum* and water [18]. Swiss albino mice were randomly allocated to six groups of 5 mice (n=5).

### Experimental design

A completely randomized experimental design was adopted in this study as described in antipyretic study. Each mouse received treatment as follows;

**Group I:** (normal control group) comprised normal mice that received 0.01ml of 2.5% formalin.

**Group II:** (negative control) received 3% DMSO.

**Group III:** (positive control) received 0.1ml of diclofenac at 15mg/kg body weight and after thirty minutes were administered with 2.5% of 0.01ml formalin as the pain inducing agent.

**Group IV:** Comprised mice that received 150mg/kg body weight of the plant extract and thirty minutes later administered with 2.5 % formalin.

**Group V:** Comprised mice that received 200mg/kg body weight of the plant extract and thirty minutes later administered with 2.5% formalin.

**Group VI:** Comprised of mice that received 250 mg/kg body weight of the plant extract and thirty minutes later administered with 2.5% formalin.

The formalin-induced pain was carried out as described by Hunskaar and Hole (1985),<sup>164</sup> where all the animals received 0.1ml of treatments intraperitoneally and 30 minutes later injected with 0.01ml of formalin (2.5%) in the left hind paw to generate pain behavior of shaking, licking, biting and lifting<sup>165,166</sup>.

The time taken a licking, shaking, biting or lifting of hind paw induced with pain was measured and recorded<sup>165</sup>. The experimentation of Swiss albino mice was done inside a transparent Plexiglas chamber with a mirror put at the side of the chamber to provide a clear observation of the animals being experimented. Two phases of intensive pain behaviors were determined and recorded singly. The early phase was measured and recorded between zero and the fifth minute while the second phase (late phase) measured and recorded between the fifteenth and thirtieth minute. The percentage of pain inhibition was computed utilizing the following formula.

$$\% \text{ of pain inhibition} = \frac{C-T}{C} \times 100$$

Where,

C = Each phase vehicle control group value

T = Each phase treated group value

### Statistical analysis

Data on pain was obtained, recorded and entered into Microsoft Excel spreadsheet. It was cleaned and then transferred for statistical analysis in Minitab statistical software (version 17.0). The data were subjected to descriptive statistics and expressed as mean  $\pm$  SEM. An inferential statistic one-way ANOVA was applied to analyze for statistical variation among various sets of treatment groups accompanied by Tukey's post hoc test for mean separations and comparison. Antinociceptive effects of the two plant extracts were carried out using unpaired student t-tested. The confidence level was set at 99.5% ( $p \leq 0.005$ ).

### Result and Discussion

#### Extract nature and extractive value

The ethanolic extract of the aerial part of the plant *Ipomoea quamoclit* was obtained as dark green in colour and the percentage yield was found to be 9.60%.

#### Pharmacological evaluation

##### Antipyretic activity

The extract of *Ipomoea quamoclit* generally exhibited *in vivo* antipyretic activities in rats, which was evidenced by a reduction in rectal temperature against turpentine induced fever. After one hour of treatment, the groups of Swiss albino rats that received aspirin (100mg/kg body weight) and the extract doses of 150, 200 and 250 mg/kg bw lowered the rectal temperature to 97.05%, 97.11%, 96.55% and 96.69% respectively (Table 6.2).

The *Ipomoea quamoclit* extract dose of 200 caused the highest antipyretic activity, which reduced pyrexia by 2.43% in the first hour. This change was higher than that caused by the reference drug, aspirin, which reduced pyrexia by 1.93%. However, the effect of aspirin was comparable to that of extracts dose levels of 150, 200 and 250 ( $p > 0.005$ ).

In the 2nd hour, the *Ipomoea quamoclit* extract reduced the elevated rectal temperature in a dose-dependent fashion. At doses of 150, 200 and 250, the extract lowered the raised rectal temperature to 95.91%, 95.77% and 95.72% respectively. The antipyretic activities of the leaf extract doses of 150 and 200 were statistically similar and comparable to that of aspirin ( $p < 0.005$ ).

In the 3rd hour post-treatment, the leaf extract doses of 150, 200 and 250 lowered the elevated rectal temperature in rats to 95.35%, 95.12%, 95.39% respectively. Similarly, at this hour the extract showed a dose-independent antipyretic potential. The rats that received the *Ipomoea quamoclit* extract at doses of 150, 200 and 250 exhibited antipyretic activities that were significantly different ( $p < 0.005$ ). However, the antipyretic activity of aspirin was statistically similar compared to that of the extract at all tested dose levels ( $p > 0.005$ ; T).

In the 4th hour, the *Ipomoea quamoclit* extract reduced raised rectal temperature in a dose-dependent manner. The extract of *Ipomoea quamoclit* doses of 150, 200 and 250 reduced pyrexia to 94.52%, 94.17%, 94.15%, respectively. At this hour, the group that received extract of *Ipomoea quamoclit* at a dose of 250 recorded the highest antipyretic effects, which was higher than that of aspirin. The antipyretic effects of the extract doses of 150, 200 and 250 were not significantly different from each other and were comparable to that of the reference drug, aspirin ( $p > 0.005$ ).


Notably, the animals in the normal control group showed no remarkable change in rectal temperature from zero to the fourth hour ( $p > 0.005$ ). However, the animals in the negative control group had a significant increase in rectal temperature from hour zero to hour three ( $p < 0.005$ ). On the other hand, there was a significant reduction in rectal temperature of rats that were treated with aspirin and *Ipomoea quamoclit* extract at all the doses tested from hour zero to the fourth hour ( $p < 0.005$ ).

**Table 1:** Antipyretic effects of *Ipomoea quamoclit* on turpentine-induced pyrexia in rat

| Group     | Treatment                 | Percentage change in rectal temperatures (°C) |                      |                      |                      |                      |
|-----------|---------------------------|-----------------------------------------------|----------------------|----------------------|----------------------|----------------------|
|           |                           | 0hr                                           | 1hr                  | 2hr                  | 3hr                  | 4hr                  |
| Group I   | 3% DMSO                   | 100.00±0.00                                   | 98.87±0.13a (0.11)   | 100.12±0.22a (-0.16) | 98.72±0.13a (0.22)   | 98.88±0.18a (0.11)   |
| Group II  | Turpentine + DMSO         | 100.00±0.00                                   | 100.41±0.06a (-0.42) | 100.11±0.10a (-0.57) | 100.65±0.18b (-0.68) | 100.51±0.12a (-0.52) |
| Group III | Turpentine + Aspirin      | 100.00±0.00                                   | 97.05±0.07cd (1.93)  | 96.52±0.15bc (2.45)  | 95.81±0.12cde (3.18) | 94.29±0.16d (4.69)   |
| Group IV  | Turpentine + 150 mg/kg bw | 100.00±0.00                                   | 97.11±0.15cd (1.87)  | 95.91±0.05cd (3.06)  | 95.35±0.09e (3.63)   | 94.52±0.07cd (4.47)  |
| Group V   | Turpentine + 200 mg/kg bw | 100.00±0.00                                   | 96.55±0.10d (2.43)   | 95.77±0.06cd (3.20)  | 95.12±0.08e (3.87)   | 94.17±0.07d (4.80)   |
| Group VI  | Turpentine + 250mg/kg bw  | 100.00±0.00                                   | 96.69±0.05d (2.29)   | 95.72±0.07d (3.27)   | 95.39±0.05e (3.59)   | 94.15±0.10d (4.83)   |

Values are expressed as mean ± SEM for 5 rats per group. Values with different superscript letters are

statistically significant ( $p \leq 0.005$ ) along the same column. The figures in brackets represent mean % inhibition.

**Fig 1:** Percentage change in rectal temperatures (°C)

### Analgesic activities

The antinociceptive activity of aerial part of *Ipomoea quamoclit* extracts was assessed by formalin-induced nociception in Swiss albino mice. They include the early phase which persisted for the first 5 minutes and the late phase which endured between the fifteenth to the thirtieth minute after injection of formalin. The animals that received leaf extract of *E. globulus* revealed analgesic activity on the formalin-induced nociception in the two phases. This was evident by a decline in paw shaking, biting, licking and lifting time.

The Swiss albino mice that received aerial part of *Ipomoea quamoclit* extracts at the dose levels of 150, 200 and 250 mg/kgbw as well as diclofenac (15mg/kg bodyweight), decreased the paw licking time by 31.71%, 29.76%, 30.57% and 31.87% respectively in the early phase. The analgesic activity of *Ipomoea quamoclit* extract at the three dosages exhibited a significant difference in the early phase ( $p < 0.005$ ). However, the analgesic effect of diclofenac was statistically insignificant compared to the effect of *Ipomoea*

*quamoclit* at dosages of 150, 200 and 250 in the early phase ( $p < 0.005$ ). The antinociceptive effect of the aerial part of *Ipomoea quamoclit* showed a dose independent response in the early phase.

The mice that were administered with aerial part ethanolic extract of *Ipomoea quamoclit* at the dose levels of 150, 200 and 250 including the aspirin lowered the paw licking time by 90.65%, 94.49%, 98.52% and 98.32% respectively in the late phase.

The analgesic activity of the extract of aerial part of *Ipomoea quamoclit* at the three dosages revealed a significant difference in the late phase ( $p < 0.005$ ). However, the analgesic activity of the diclofenac was comparable to that of extract of aerial part of *Ipomoea quamoclit* at a dose of 250 in the late phase ( $p > 0.005$ ). The analgesic effect of the extract of aerial part of *Ipomoea quamoclit* showed a dose dependent response in the late phase. In comparison, the analgesic effect of extract of aerial part of *Ipomoea quamoclit* at all the three dose levels was significantly effective at the late phase compared to the early phase in mice ( $p < 0.005$ ).

**Table 2:** analgesic activity *Ipomoea quamoclit* aerial part extract on formalin-induced pain in mice

| Group     | Treatment                        | Early Phase (1-5 min) | Late Phase (15-30 min) |
|-----------|----------------------------------|-----------------------|------------------------|
| Group I   | 3% DMSO                          | 0.00±0.00e (0.00)     | 0.00 ±0.00h (0.00)     |
| Group II  | DMSO + Formalin                  | 121.00±1.55a (100.00) | 293.40±9.58a (100.00)  |
| Group III | Diclofenac 15mg/kg bw + Formalin | 82.77± 1.39d (31.87)  | 4.00±0.89g (98.32)     |
| Group IV  | 150mg/kg bw + Formalin           | 83.01±0.55d (31.71)   | 26.78±1.16e (90.65)    |
| Group V   | 200mg/kg bw + Formalin           | 85.34±1.96d (29.76)   | 15.39±1.03f (94.49)    |
| group VI  | 250mg/kg bw + Formalin           | 84.39±1.78d (30.57)   | 3.37±0.75g (98.52)     |

Values are expressed as mean ± SEM for 5 mice. Values with a different superscript letter are statistically significant along the same column by one-way ANOVA followed by Turkey's

post hoc test ( $p \leq 0.005$ ). The values in brackets represent % pain inhibition.




Fig 2: Analgesic activity Ipomoea quamoclit




Fig 3: % pain inhibition

The analgesic activities of the extract of aerial part of *Ipomoea quamoclit* exhibited no significant difference at the doses of 150 and 200 in the latephase ( $p > 0.005$ ; Figure 5.4).

### Conclusions

This study revealed that the *Ipomoea quamoclit* extracts possess potent antipyretic and analgesic activities. The study also revealed that the effects of plant extract at doses of 200 and 250mg/kg bw were comparable with that of the reference drugs, aspirin and diclofenac. The synergistic and additive effects of the bioactive constituents increase their bioavailability and action on multiple molecular targets thus, the observed activities of *Ipomoea quamoclit* extract is attributed to secondary metabolites they contain. This study, therefore, confirms and supports the use of the studied plant extracts as an alternative and/or complementary remedy against pain and fever. The study also sets the pace for further studies in an effort to develop plant-derived drug compounds for the treatment of pain, fever and inflammation.

From this study, it is concluded that;

1. The ethanolic extract of aerial part of *Ipomoea quamoclit* has several phytochemical agents associated with antipyretic activity in rats.
2. The ethanolic extract of aerial part of *Ipomoea quamoclit* contain phytochemical compounds associated with antinociceptive potential in mice.
3. The ethanolic extract of aerial part of *Ipomoea quamoclit* contain phytochemical compounds associated with anti-inflammatory activity in mice.

Therefore, the research questions formulated in this study were answered in the affirmative and the study objectives were successfully executed and achieved.

### References

1. Székely M, Garai J. Thermoregulation and age. In: Handbook of Clinical Neurology. 2018;156:377-95. Elsevier.
2. Tohidpour A, Morgun AV, Boitsova EB, Malinovskaya NA, Martynova GP, Khilazheva ED, et al. Neuroinflammation and infection: molecular mechanisms associated with dysfunction of the neurovascular unit. Frontiers in Cellular and Infection Microbiology. 2017;7:276.
3. Anochie IP. Mechanisms of fever in humans. International Journal of Microbiology and Immunology Research. 2013;2(5):37-43.
4. Barbi E, Marzuillo P, Neri E, Naviglio S, Krauss BS. Fever in children: pearls and pitfalls. Children. 2017;4(9):81-100.
5. Cabral A, Valdivia S, Reynaldo M, Cyr NE, Nillni EA, Perello M. Short-term cold exposure activates TRH neurons exclusively in the hypothalamic paraventricular nucleus and raphe pallidus. Neuroscience Letters. 2012;518(2):86-91.
6. Ward JP, Linden RW. Physiology at a Glance. John Wiley & Sons; c2017.
7. Patel MD, Patel JH, Rajput MB, Bariya AR. Adaptive

- physiological and biochemical responses of dairy animals to heat stress: a review. *International Journal of Applied and Natural Sciences*. 2016;5(1):107-16.
8. Srilakshmi D, Sachchidananda SG. *World Journal of Pharmaceutical Sciences*. 2018;6(6):112-5.
  9. Singh A, Klapper A, Jia J, Fidalgo A, Tajadura-Jiménez A, Kanakam N, *et al*. Motivating people with chronic pain to do physical activity: opportunities for technology design. In: *Proceedings of the SIGCHI Conference on Human Factors in Computing Systems*. 2014:2803-12.
  10. Rio E, Moseley L, Purdam C, Samiric T, Kidgell D, Pearce AJ, *et al*. The pain of tendinopathy: physiological or pathophysiological? *Sports Medicine*. 2014;44(1):9-23.
  11. Díaz-Rodríguez L, García-Martínez O, Morales MA, Rodríguez-Pérez L, Rubio-Ruiz B, Ruiz C. Effects of indomethacin, nimesulide, and diclofenac on human MG-63 osteosarcoma cell line. *Biological Research for Nursing*. 2012;14(1):98-107.
  12. Gelband H, Sankaranarayanan R, Gauvreau CL, Horton S, Anderson BO, Bray F, *et al*. Costs, affordability, and feasibility of an essential package of cancer control interventions in low- and middle-income countries: key messages from Disease Control Priorities. *The Lancet*. 2016;387(10033):2133-44.
  13. Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. In: *Seminars in Arthritis and Rheumatism*. 2014;44(2):145-54. W.B Saunders.
  14. Hogans BB, Barreveld AM, editors. *Pain Care Essentials*. Oxford University Press; c2019.
  15. Porta-Sales J, Nabal-Vicuna M, Vallano A, Espinosa J, Planas-Domingo J, Verger-Fransoy E, *et al*. Have we improved pain control in cancer patients? A multicenter study of ambulatory and hospitalized cancer patients. *Journal of Palliative Medicine*. 2015;18(11):923-32.
  16. Franceschi F, Marsiliani D, Alesi A, Mancini MG, Ojetti V, Candelli M, *et al*. A simplified way for the urgent treatment of somatic pain in patients admitted to the emergency room: the SUPER algorithm. *Internal and Emergency Medicine*. 2015;10(8):985-92.
  17. Nostro AM, Germano AV, D'Angelo A, Marino A, Cannatelli MA. Extraction methods and bioautography for evaluation of medicinal plant antimicrobial activity. *Letters in Applied Microbiology*. 2000;30:379-84.
  18. Khandelwal KR. *Practical Pharmacognosy*. 2nd ed. Pune: Nirali Prakashan; 2000:11-6, 65, 78, 149-53, 157-9, 164.
  19. OECD. Guidelines for testing of chemicals, revised draft 420: documents on acute oral toxicity and acute toxicity class method. Revised Dec; c2001.
  20. Vogel HG. *Drug Discovery and Evaluation: Pharmacological Assays*. Springer-Verlag Berlin Heidelberg; 2002:2-716.